Loading company…
Prazer Therapeutics develops drugs for refractory diseases using its protein-degradation technology.
Prazer Therapeutics develops treatments for refractory diseases, including neurodegenerative, inflammatory, and viral conditions. Its SPiDEM™ technology uses small molecules to target protein aggregates and other proteins. Founded in 2019, the company is based in Seoul, South Korea. In July 2026, it raised KRW 50 billion in pre-IPO funding led by Playground Ventures and Shinhan Asset Management, with returning investors including Johnson & Johnson Innovation and WOORI Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in